Overview
Background
Dr Kitty St Pierre is a Lecturer within the School of Pharmacy and Pharmaceutical Sciences, and a Senior Research Pharmacist with Queensland Health. Her research interests include clinical pharmacy and medication management, particularly in the fields of kidney disease and stroke.
Availability
- Dr Kitty St Pierre is:
- Available for supervision
Qualifications
- Bachelor (Honours) of Pharmacy, The University of Queensland
- Doctor of Philosophy of Pharmacy, The University of Queensland
Works
Search Professor Kitty St Pierre’s works on UQ eSpace
2026
Journal Article
Caring for Australians and <scp>New ZealandeRs</scp> with kidney <scp>Impairment</scp> guideline commentary on kidney disease: improving global outcomes 2025 guidelines for diagnosis and management of autosomal polycystic kidney disease
Abdy, Mia E., St Pierre, Kitty, Major, Emily, Alexander, Stephen I., Cashmore, Brydee, Coolican, Helen, Cullen, Vanessa, Dawson, Jessica, Lambert, Kelly, Lee, Vincent W., Mallawaarachi, Amali, Rangan, Gopala, Savige, Judy, Varughese, Santosh, Tunnicliffe, David J., Mallett, Andrew J. and the CARI Guidelines Steering Committee (2026). Caring for Australians and New ZealandeRs with kidney Impairment guideline commentary on kidney disease: improving global outcomes 2025 guidelines for diagnosis and management of autosomal polycystic kidney disease. Internal Medicine Journal imj.70411. doi: 10.1111/imj.70411
2026
Journal Article
Shaping future deprescribing priorities: outcomes of a World Café stakeholder workshop
Olsen, William Manning, St Pierre, Kitty, Thompson, Wade, Weir, Kristie Rebecca, Freeman, Christopher Robert, Bohill, Ruth, Farrell, Barbara, Langford, Aili Veronica, O'Donnell, Lisa Kouladjian, Reeve, Emily, Liau, Shin J, McEvoy, Aisling Mary, Shrestha, Shakti, Tesfaye, Wubshet, Breen, Juanita, Etherton-Beer, Christopher, Yik, Jerry, Turner, Justin and Ailabouni, Nagham J. (2026). Shaping future deprescribing priorities: outcomes of a World Café stakeholder workshop. Expert review of clinical pharmacology, 19 (1), 85-96. doi: 10.1080/17512433.2025.2609659
2025
Journal Article
Endpoint selection in autosomal dominant polycystic kidney disease clinical trials
St Pierre, Kitty, El-Damanawi, Ragada, Jefferis, Julia, Johnson, David W., Hawley, Carmel M., Staatz, Christine E., Viecelli, Andrea K. and Mallett, Andrew J. (2025). Endpoint selection in autosomal dominant polycystic kidney disease clinical trials. Kidney International Reports, 10 (11), 3773-3784. doi: 10.1016/j.ekir.2025.09.024
2025
Journal Article
Methods for living guidelines: Paper 6: Insights from ALEC’s use of existing systematic reviews in living guideline development
St Pierre, Kitty, Cashmore, Brydee, Cumpston, Miranda S., Hill, Kelvin, McDonald, Steve, Pattuwage, Loyal, White, Heath, Whittle, Samuel L., Turner, Tari and Tunnicliffe, David J. (2025). Methods for living guidelines: Paper 6: Insights from ALEC’s use of existing systematic reviews in living guideline development. Journal of Clinical Epidemiology, 187 111812, 1-13. doi: 10.1016/j.jclinepi.2025.111812
2025
Journal Article
Implementation of Metformin Therapy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD): study protocol for a phase III, multi-centre, randomized, placebo-controlled trial evaluating the long-term efficacy of metformin in slowing the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease
St Pierre, Kitty, El-Damanawi, Ragada, Johnson, David W., Hawley, Carmel M., Viecelli, Andrea K., Jha, Vivekanand, Green, Suetonia C., Gesualdo, Loreto, Kiriwandeniya, Charani, Velayudham, Pushparaj, Vergara, Liza A., Mihala, Gabor, Matsuyama, Misa, Brent, Peta-Ann Paul, Mallett, Andrew J. and IMPEDE-PKD Global Steering Committee (2025). Implementation of Metformin Therapy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD): study protocol for a phase III, multi-centre, randomized, placebo-controlled trial evaluating the long-term efficacy of metformin in slowing the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease. Trials, 26 (1) 302. doi: 10.1186/s13063-025-09010-6
2025
Other Outputs
Establishing the role of metformin for ADPKD through therapeutic investigation and guideline development
St Pierre, Kitty (2025). Establishing the role of metformin for ADPKD through therapeutic investigation and guideline development. PhD Thesis, Faculty of Medicine, The University of Queensland. doi: 10.14264/b82c120
2025
Book Chapter
Considering kidney and liver function when prescribing and reviewing medicines in older people
St Pierre, Kitty I., Hill, Katherine and Staatz, Christine E. (2025). Considering kidney and liver function when prescribing and reviewing medicines in older people. Polypharmacy and geriatrics. (pp. 207-229) edited by Nagham J. Ailabouni. Cham, Switzerland: Springer Cham. doi: 10.1007/978-3-031-77314-3_8
2024
Journal Article
Interventions for preventing the progression of autosomal dominant polycystic kidney disease
St Pierre, Kitty, Cashmore, Brydee A, Bolignano, Davide, Zoccali, Carmine, Ruospo, Marinella, Craig, Jonathan C, Strippoli, Giovanni FM, Mallett, Andrew J, Green, Suetonia C and Tunnicliffe, David J (2024). Interventions for preventing the progression of autosomal dominant polycystic kidney disease. Cochrane Database of Systematic Reviews, 2024 (10) CD010294, CD010294-10. doi: 10.1002/14651858.CD010294.pub3
2024
Journal Article
Metformin for preventing the progression of chronic kidney disease
El-Damanawi, Ragada, Stanley, Isabelle Kitty, Staatz, Christine, Pascoe, Elaine M., Craig, Jonathan C., Johnson, David W., Mallett, Andrew J., Hawley, Carmel M., Milanzi, Elasma, Hiemstra, Thomas F. and Viecelli, Andrea K. (2024). Metformin for preventing the progression of chronic kidney disease. Cochrane Database of Systematic Reviews, 2024 (6) CD013414, CD013414. doi: 10.1002/14651858.cd013414.pub2
2024
Journal Article
A secondary analysis of concurrent use of metformin and tolvaptan in ADPKD tolvaptan trials
Stanley, I. Kitty, Palma, Anton M., Viecelli, Andrea K., Johnson, David W., Hawley, Carmel M., Staatz, Christine E. and Mallett, Andrew J. (2024). A secondary analysis of concurrent use of metformin and tolvaptan in ADPKD tolvaptan trials. Journal of Nephrology, 37 (5), 1417-1419. doi: 10.1007/s40620-024-01906-x
2024
Journal Article
A post hoc analysis of the CKD-FIX study analysing the association between metformin usage and eGFR decline
Stanley, Kitty, Mallett, Andrew J., Viecelli, Andrea K., Hawley, Carmel M., Staatz, Christine E., Johnson, David W. and Milanzi, Elasma (2024). A post hoc analysis of the CKD-FIX study analysing the association between metformin usage and eGFR decline. Kidney International Reports, 9 (5), 1525-1527. doi: 10.1016/j.ekir.2024.02.011
2023
Conference Publication
INTERVENTIONS FOR PREVENTING THE PROGRESSION OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE. A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS
Stanley, Isabelle Kitty, Palmer, Suetonia, Mallett, Andrew, Johnston, Brydee and Tunnicliffe, David (2023). INTERVENTIONS FOR PREVENTING THE PROGRESSION OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE. A COCHRANE SYSTEMATIC REVIEW AND META-ANALYSIS. HOBOKEN: WILEY.
2023
Conference Publication
A Secondary Analysis of Concurrent use of Metformin and Tolvaptan in ADPKD Tolvaptan Trials
Stanley, I., Palma, A., Viecelli, A., Johnson. D., Hawley, C., Staatz, C. and Mallett, A. (2023). A Secondary Analysis of Concurrent use of Metformin and Tolvaptan in ADPKD Tolvaptan Trials. Asian Pacific Society of Dialysis Access (APSDA) Conference, Cairns, QLD Australia, 22-24th October 2023. HOBOKEN: WILEY.
2023
Conference Publication
A post-hoc analysis of the CKD-FIX study analysing the association between metformin use and eGFR decline
Stanley, I., Viecelli, A., Johnson, D., Hawley, C., Mallett, A., Staatz, C. and Milanzi, E. (2023). A post-hoc analysis of the CKD-FIX study analysing the association between metformin use and eGFR decline. Australian and New Zealand Society of Nephrology Conference, Cairns, QLD, Australia, 22-24 October 2023. HOBOKEN: WILEY.
2022
Journal Article
Caring for Australians and New Zealanders With Kidney Impairment guidelines: rapid development of urate lowering therapy guidelines for people with CKD
Stanley, Isabelle Kitty, Phoon, Richard K. S., Toussain, Nigel D., Cullen, Vanessa, Kearns, John, Dalbeth, Nicola, Johnson, David W., Krishnasamy, Rathika and Tunnicliffe, David J. (2022). Caring for Australians and New Zealanders With Kidney Impairment guidelines: rapid development of urate lowering therapy guidelines for people with CKD. Kidney International Reports, 7 (12), 2563-2574. doi: 10.1016/j.ekir.2022.09.024
2021
Journal Article
Evaluating the utilisation and expenditure patterns of erythropoietin stimulating agents and immunosuppressants in Australian chronic kidney disease patients
Stanley, Isabelle Kitty, Schultz, Kadin L., Gardiner, Kyle M. and Staatz, Christine E. (2021). Evaluating the utilisation and expenditure patterns of erythropoietin stimulating agents and immunosuppressants in Australian chronic kidney disease patients. Journal of Pharmaceutical Health Services Research, 12 (3), 350-356. doi: 10.1093/jphsr/rmab027
Supervision
Availability
- Dr Kitty St Pierre is:
- Available for supervision
Looking for a supervisor? Read our advice on how to choose a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
What are the barriers to, and facilitators of, implementing AI-driven medication management tools across healthcare , and how can these challenges beaddressed?
Associate Advisor
Other advisors: Professor Michael Barras, Professor Ian Scott, Dr Nazanin Ghahreman-Falconer
Media
Enquiries
For media enquiries about Dr Kitty St Pierre's areas of expertise, story ideas and help finding experts, contact our Media team: